In Vitro three-dimensional (3D) cell culture tools for spheroid and organoid models

IF 2.7 4区 生物学 Q2 BIOCHEMICAL RESEARCH METHODS SLAS Discovery Pub Date : 2023-06-01 DOI:10.1016/j.slasd.2023.03.006
Sang-Yun Lee , In-Seong Koo , Hyun Ju Hwang , Dong Woo Lee
{"title":"In Vitro three-dimensional (3D) cell culture tools for spheroid and organoid models","authors":"Sang-Yun Lee ,&nbsp;In-Seong Koo ,&nbsp;Hyun Ju Hwang ,&nbsp;Dong Woo Lee","doi":"10.1016/j.slasd.2023.03.006","DOIUrl":null,"url":null,"abstract":"<div><p>Three-dimensional (3D) cell culture technology has been steadily studied since the 1990′s due to its superior biocompatibility compared to the conventional two-dimensional (2D) cell culture technology, and has recently developed into an organoid culture technology that further improved biocompatibility. Since the 3D culture of human cell lines in artificial scaffolds was demonstrated in the early 90′s, 3D cell culture technology has been actively developed owing to various needs in the areas of disease research, precision medicine, new drug development, and some of these technologies have been commercialized. In particular, 3D cell culture technology is actively being applied and utilized in drug development and cancer-related precision medicine research. Drug development is a long and expensive process that involves multiple steps—from target identification to lead discovery and optimization, preclinical studies, and clinical trials for approval for clinical use. Cancer ranks first among life-threatening diseases owing to intra-tumoral heterogeneity associated with metastasis, recurrence, and treatment resistance, ultimately contributing to treatment failure and adverse prognoses. Therefore, there is an urgent need for the development of efficient drugs using 3D cell culture techniques that can closely mimic <em>in vivo</em> cellular environments and customized tumor models that faithfully represent the tumor heterogeneity of individual patients. This review discusses 3D cell culture technology focusing on research trends, commercialization status, and expected effects developed until recently. We aim to summarize the great potential of 3D cell culture technology and contribute to expanding the base of this technology.</p></div>","PeriodicalId":21764,"journal":{"name":"SLAS Discovery","volume":"28 4","pages":"Pages 119-137"},"PeriodicalIF":2.7000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"SLAS Discovery","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S247255522300028X","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 5

Abstract

Three-dimensional (3D) cell culture technology has been steadily studied since the 1990′s due to its superior biocompatibility compared to the conventional two-dimensional (2D) cell culture technology, and has recently developed into an organoid culture technology that further improved biocompatibility. Since the 3D culture of human cell lines in artificial scaffolds was demonstrated in the early 90′s, 3D cell culture technology has been actively developed owing to various needs in the areas of disease research, precision medicine, new drug development, and some of these technologies have been commercialized. In particular, 3D cell culture technology is actively being applied and utilized in drug development and cancer-related precision medicine research. Drug development is a long and expensive process that involves multiple steps—from target identification to lead discovery and optimization, preclinical studies, and clinical trials for approval for clinical use. Cancer ranks first among life-threatening diseases owing to intra-tumoral heterogeneity associated with metastasis, recurrence, and treatment resistance, ultimately contributing to treatment failure and adverse prognoses. Therefore, there is an urgent need for the development of efficient drugs using 3D cell culture techniques that can closely mimic in vivo cellular environments and customized tumor models that faithfully represent the tumor heterogeneity of individual patients. This review discusses 3D cell culture technology focusing on research trends, commercialization status, and expected effects developed until recently. We aim to summarize the great potential of 3D cell culture technology and contribute to expanding the base of this technology.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
体外三维(3D)细胞培养工具,用于球体和类器官模型
与传统的二维细胞培养技术相比,三维细胞培养技术由于其优越的生物相容性,自20世纪90年代以来一直在稳步研究,最近已发展成为一种进一步提高生物相容性的类器官培养技术。自90年代初在人工支架中进行人体细胞系的3D培养以来,由于疾病研究、精准医学、新药开发等领域的各种需求,3D细胞培养技术得到了积极发展,其中一些技术已经商业化。特别是3D细胞培养技术在药物开发和癌症相关精准医学研究中得到了积极的应用和利用。药物开发是一个漫长而昂贵的过程,涉及多个步骤——从靶点识别到先导发现和优化、临床前研究,以及临床使用批准的临床试验。癌症在危及生命的疾病中排名第一,因为肿瘤内的异质性与转移、复发和治疗耐药性相关,最终导致治疗失败和不良预后。因此,迫切需要使用3D细胞培养技术开发有效的药物,该技术可以密切模拟体内细胞环境,并定制肿瘤模型,忠实地代表个体患者的肿瘤异质性。这篇综述讨论了3D细胞培养技术,重点是研究趋势、商业化现状和最近开发的预期效果。我们旨在总结3D细胞培养技术的巨大潜力,并为扩大该技术的基础做出贡献。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
SLAS Discovery
SLAS Discovery Chemistry-Analytical Chemistry
CiteScore
7.00
自引率
3.20%
发文量
58
审稿时长
39 days
期刊介绍: Advancing Life Sciences R&D: SLAS Discovery reports how scientists develop and utilize novel technologies and/or approaches to provide and characterize chemical and biological tools to understand and treat human disease. SLAS Discovery is a peer-reviewed journal that publishes scientific reports that enable and improve target validation, evaluate current drug discovery technologies, provide novel research tools, and incorporate research approaches that enhance depth of knowledge and drug discovery success. SLAS Discovery emphasizes scientific and technical advances in target identification/validation (including chemical probes, RNA silencing, gene editing technologies); biomarker discovery; assay development; virtual, medium- or high-throughput screening (biochemical and biological, biophysical, phenotypic, toxicological, ADME); lead generation/optimization; chemical biology; and informatics (data analysis, image analysis, statistics, bio- and chemo-informatics). Review articles on target biology, new paradigms in drug discovery and advances in drug discovery technologies. SLAS Discovery is of particular interest to those involved in analytical chemistry, applied microbiology, automation, biochemistry, bioengineering, biomedical optics, biotechnology, bioinformatics, cell biology, DNA science and technology, genetics, information technology, medicinal chemistry, molecular biology, natural products chemistry, organic chemistry, pharmacology, spectroscopy, and toxicology. SLAS Discovery is a member of the Committee on Publication Ethics (COPE) and was published previously (1996-2016) as the Journal of Biomolecular Screening (JBS).
期刊最新文献
Varieties of interactions of anti-CD133 aptamers with cell cultures from patient glioblastoma TGF-β receptor-specific NanoBRET Target Engagement in living cells for high-throughput kinase inhibitor screens The development of a novel high-throughput membrane potential assay and a solid-supported membrane (SSM)-based electrophysiological assay to study the pharmacological inhibition of GLUT9/SLC2A9 isoforms in a drug discovery program The history, landscape, and outlook of human cell line authentication and security Development of a live cell assay for real-time monitoring the interactions between the Hippo pathway components 14-3-3 and TAZ
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1